Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group

Summary While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis tha...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of haematology Vol. 186; no. 2; pp. 274 - 285
Main Authors:	Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O'Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.07.2019
Subjects:	acute lymphoblastic leukaemia Acute lymphoblastic leukemia acute lymphocytic leukaemia Adolescent Adult Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Chemotherapy Child Child, Preschool Children Clinical trials Diagnosis Disease-Free Survival Female Hematology Humans Infant Leukemia Lymphoma Male Minimal residual disease Neoplasm, Residual Oncology paediatric leukaemia Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality proteasome inhibition Proteasome inhibitors Recurrence Survival Rate Time Factors proteasome inhibition acute lymphocytic leukaemia minimal residual disease acute lymphoblastic leukaemia paediatric leukaemia
ISSN:	0007-1048, 1365-2141, 1365-2141
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!